Supplemental Information

Enhancing Chemoradiation of Colorectal Cancer Through Targeted Delivery of Raltitrexed by Hyaluronic Acid Coated Nanoparticles

Justin G. Rosch\textsuperscript{a}, Madeleine R. Landry\textsuperscript{a}, Charles R. Thomas, Jr.\textsuperscript{b}, and Conroy Sun\textsuperscript{a,b,*}

\textsuperscript{a} Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR 97201, USA

\textsuperscript{b} Department of Radiation Medicine, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA

*Corresponding Author:

Conroy Sun, Ph.D.
Department of Pharmaceutical Sciences
Oregon State University
2730 SW Moody Ave
Portland, OR 97201-5041, USA
Email: sunc@ohsu.edu
Phone: 503-346-4699
Figure S1. TEM of bare CML nanoparticles prior to layer-by-layer deposition.

Figure S2. Fluorescence microscopy images of no treatment and CML-PLA-HA treated wells after 24 h exposure. The no treatment well is the same as presented in Figure 3. The hyaluronic acid only nanoparticles showed similar fluorescence to the HARPs.
Figure S3. 24, 48, and 72 h viability curves for raltrexed and HARPs.
Figure S4. Stacked histograms showing the changing fluorescent signal with different treatments (γH2AX assay).